Archived Press Releases – 2018

4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products

Emeryville, CA, April 30, 2018 — 4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced the expansion of its 2015 research agreement with F. Hoffmann-La Roche ...

MedImmune and 4D Molecular Therapeutics Collaborate to Design, Develop and Commercialize AAV Gene Therapy for Chronic Lung Disease

July 10, 2018 Emeryville, Ca, USA — MedImmune, the global biologics research and development arm of AstraZeneca, and 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced ...

4D Molecular Therapeutics Raises $90 Million Series B Financing

- Proceeds advance proprietary next-generation Therapeutic Vector Evolution platform and pipeline of AAV gene therapy clinical candidates - - Lead product candidate 4D-110 in Choroideremia to enter clinic in 2019 - - Financing led by Viking Global Investors - Emeryville, ...

4D Molecular Therapeutics to Participate at Upcoming Investor Conferences

Emeryville, CA – November 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that company management will participate at the following upcoming investor ...

4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremia

Emeryville, CA – November 16, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced that the U.S. Food and Drug Administration (FDA) has ...

4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Science University’s Casey Eye Institute and Oregon National Primate Research Center

Emeryville, CA – December 6, 2018 - 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development today announced a research and development collaboration with the Casey Eye Institute ...